J

Janux Therapeutics

Clinical-stage biotech developing tumor-activated immunotherapies

Vice President of Investor Relations & Corporate Communications

PR & CommunicationsConfirmed live in the last 24 hours
Full-time

About the Job

Requirements

  • A bachelor's degree in Finance, Biology, Communications, or a related field is required; an advanced degree (MBA, PhD, or MS) is preferred.
  • A minimum of 12–15 years of progressive leadership experience in investor relations and/or corporate communications within biotechnology, pharmaceuticals, or life sciences, including substantial leadership experience.
  • Significant oncology experience is required, including experience supporting innovative therapeutic platforms and complex modalities such as T-cell engagers, bispecific antibodies, CAR-T or cell therapies, antibody-drug conjugates, or other advanced biologics.
  • Exceptional communication skills and the ability to translate complex scientific and business developments into clear, compelling narratives.
  • Strong understanding of capital markets, investor behavior, and biotechnology valuation drivers.
  • Deep knowledge of SEC regulations, Regulation FD, disclosure obligations, corporate governance practices, and investor relations best practices.
  • Established relationships with key investors, analysts, and media in the healthcare and life sciences sectors.
  • Experience with investor relations and communications platforms and tools, and with managing external agencies, budgets, and performance measurement.
  • Ability to influence and partner with cross-functional teams and senior stakeholders, with executive presence and demonstrated ability to counsel senior leaders.
  • Experience building or significantly developing investor relations and corporate communications capabilities, infrastructure, and best practices.
  • Experience supporting publicly traded biotechnology companies through significant clinical, regulatory, corporate development, and financing milestones.
  • Strong writing and editorial judgment across scientific, corporate, investor, media, and employee audiences.
  • High integrity and commitment to ethical standards.
  • United States work authorization is required.

Responsibilities

  • Develop and execute an investor relations and corporate communications strategy aligned with company mission, pipeline priorities, business objectives, and long-term value creation.
  • Shape the corporate narrative, brand identity, positioning, and messaging frameworks to strengthen visibility, credibility, and reputation among key stakeholders.
  • Build and cultivate relationships with institutional investors, analysts, and banking partners, serving as the primary point of contact for the investment community.
  • Lead investor engagement and targeting activities, including conferences, non-deal roadshows, R&D and Analyst Days, key opinion leader webinars, analyst meetings, and other investor events.
  • Develop and execute shareholder targeting and ownership strategies to attract and retain long-term institutional investors aligned with the company's investment thesis.
  • Prepare senior leadership for investor conferences, non-deal roadshows, and other high-profile investor interactions, including leading key-message development, FAQs, Q&A documents, briefing materials, and response frameworks.
  • Oversee investor-facing and public communications, including earnings materials, investor presentations, scripts, press releases, website content, talking points, and executive briefing materials.
  • Lead communications planning and support execution around clinical and regulatory milestones, corporate transactions, partnerships, and financing activities.
  • Manage an integrated communications calendar and agenda coordinating investor, media, corporate, and internal communications.
  • Serve as a designated external representative to the investment community and media, following company disclosure policies and communication protocols.
  • Monitor investor sentiment, stock performance, analyst commentary and coverage, peer performance, and capital markets trends; synthesize insights to inform company strategy and messaging.
  • Track sell-side models and compare them with internal forecasts to anticipate market expectations and strengthen external communications.
  • Partner with Legal and Finance to ensure consistency, accuracy, and compliance in external communications and public disclosures, including earnings communications, investor materials, SEC disclosures, Regulation FD requirements, disclosure policies, and material-event communications.
  • Provide strategic insights and recommendations to executive leadership and the Board on market positioning, investor perceptions, shareholder communications, and reputational risk.
  • Partner with Finance and Legal on earnings preparation, disclosure governance, financing activities, and public-company communication best practices.
  • Partner with Clinical, Project Management, Regulatory, Human Resources, Finance, and Legal to ensure communications are accurate, coordinated, and appropriate for each audience.
  • Lead external investor relations and communications agencies and consultants, including scope, budgets, performance oversight, and program measurement.

Desired Qualifications

  • Autoimmune experience is highly preferred.
  • Remote work may be permitted upon approval; the role may require travel up to 25% for meetings or site visits.

About the Company

Janux Therapeutics

Clinical-stage biotech developing tumor-activated immunotherapies

Janux Therapeutics develops cancer immunotherapies that activate the immune system inside tumors to attack cancer while sparing healthy tissue. Its products are tumor-activated and use a proprietary platform masking technology to reduce toxic side effects and improve efficacy compared with traditional T cell engagers. The company advances drug candidates through clinical trials, aiming for regulatory approval and eventual commercialization, with revenue expected from partnerships, licensing, and the sale of approved therapies. Its lead program JANX007 is being evaluated in a Phase 1 trial (ENGAGER PSMA 01) for metastatic prostate cancer to assess safety and preliminary effectiveness.

Company size
51-200
Company stage
IPO
Headquarters
San Diego, CA
Founded
2017

Recently Posted Jobs

Explore more opportunities at Janux Therapeutics

See more jobs